Levetir
Levetir
Levetir
100 mg/mL, 5 mL vial
Registration Number 衛署藥製字第057956號
Indications
The following epilepsy patients who are temporarily unsuitable or unable to be treated with oral anti-epileptic drugs: Individual treatment of localized epileptic seizures (with or without secondary generalized seizures) in patients over 16 years old. Partial epileptic seizures (with or without secondary generalized seizures) in children and adults over four years old, myotonic seizures in adolescents and adult patients over twelve years old, and adolescent and adult patients over sixteen years old and Adjuvant treatment of primary generalized tonic-clonic seizures in adults with constitutional generalized epilepsy.
product details
| Name | Levetir |
| Registration Number | 衛署藥製字第057956號 |
| Generic Name | Levetiracetam |
| Territory | Taiwan |
| Package | 100 mg/mL, 5 mL vial |
| Indication | The following epilepsy patients who are temporarily unsuitable or unable to be treated with oral anti-epileptic drugs: Individual treatment of localized epileptic seizures (with or without secondary generalized seizures) in patients over 16 years old. Partial epileptic seizures (with or without secondary generalized seizures) in children and adults over four years old, myotonic seizures in adolescents and adult patients over twelve years old, and adolescent and adult patients over sixteen years old and Adjuvant treatment of primary generalized tonic-clonic seizures in adults with constitutional generalized epilepsy. |
| Storage | Below 25℃ |
Adverse Reaction Contact
24 hour phone: +886-800-035-511
email : pharmacovigilance@ubi-pharma.com